A large proportion of women in Odisha, India, use reusable absorbents to manage their menstruation. Yet, the risk factors for lower reproductive tract infections (RTIs) related to menstrual hygiene management (MHM) have not been studied among reusable absorbent users. Women of reproductive age attending one of two hospitals from two different cities in Odisha during two separate study intervals were recruited for the study. Laboratory diagnosis of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) were conducted. A questionnaire was used to collect information on MHM practices, water, sanitation, and socio-demographic factors. Among the 509 women who used reusable absorbents, 71.7% were diagnosed with at least one infection. After adjusting for confounders, women with BV were more likely to identify as being a housewife (aOR: 1.8 (1.1–2.9)). Frequent absorbent changing was protective against BV (aOR: 0.5 (0.3–0.8)), whereas frequent body washing increased the odds of BV (aOR: 1.5 (1.0–2.2)). Women with VVC were more likely to be older (aOR: 1.6 (1.0–2.5)), live below the poverty line (aOR: 1.5 (1.1–2.2)), have a non-private household latrine (aOR: 2.2 (1.3–4.0)), dry their absorbents inside the house (aOR: 3.7 (2.5–4.5)), and store absorbents in the latrine area (aOR: 2.0 (1.3–2.9)). Washing absorbents outside the house was protective against VVC (aOR: 0.7 (0.4–1.0)). This study highlights the importance of improving MHM practices among reusable absorbent users to prevent lower RTIs among women reusing menstrual materials in Odisha.
1 May 2018 in Journal of Infection and Public Health
Sickle-cell-gene has a high frequency in malaria endemic regions. In India, though the prevalence of both sickle-cell-gene and malaria are high, no study has been carried out. This study aims to find out the possible differences in hematological and clinical parameters in severe falciparum malaria with respect to sickle cell genotypes. Five hundred fourteen adults with severe falciparum malaria hospitalized in Department of Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, between August, 2010 to December, 2014 were included and categorized on the basis of sickle cell genotypes. The hematological parameters were compared by one-way-analysis-of-variance and incidence of sub-phenotypes of severe malaria was compared by χ2 test across the groups. Patients with sickle cell anemia (HbSS) and severe falciparum malaria had lower hemoglobin level compared to patients with normal β-globin genotype (HbAA) and sickle cell trait (HbAS). Most of the hematological parameters were homogeneous in patients with HbAA and HbAS and different from patients with HbSS. Incidence of acute renal failure was low (χ2, 9.91; p, 0.002) and jaundice was high (χ2, 5.20; p, 0.022) in patients with HbSS. No clinical difference was observed in patients with HbAA and HbAS. The mortality was low (χ2, 4.33; p, 0.037) and high (χ2, 10.48; p, 0.001) in patients with HbAS and HbSS respectively compared to patients with HbAA. Though sickle-cell-gene protects against falciparum infections, the hematological parameters and sub-phenotypes of severe malaria remain unchanged when the infection progresses to a severe form in patients with HbAA and HbAS. Presence of hemolytic anemia in patients with HbSS shows diverse hematological and clinical phenotypes as compared to others. High mortality in patients with HbSS emphasizes the need for a better preventive approach to save valuable lives.
Cancer treatment faces significant difficulties with chemotherapy, often leading to severe side effects. This encourages the need for research on innovative, selective therapies for targeted drug delivery, particularly using nanotechnology-based liposomes as carriers. Liposomes, spherical nanocarriers, can encapsulate drugs and be functionalized for targeted delivery, boosting drug accumulation in cancer cells while minimizing harm to healthy tissues. However, to introduce the targeting ability, the attachment of biomarkers with liposomes always faces several challenges such as insufficient and unstable binding, improper functionalization, poor stability, and a tedious attachment process. This study developed an antibody-functionalized liposomal system, covalently conjugated with Atezolizumab, a monoclonal antibody against programmed death-ligand 1 (PD-L1) to form antibody-lipid-doxorubicin (Ab-Lip-Dox), a targeted nanocarrier system. Unlike conventional attachment methods, this study employs a covalent conjugation strategy based on click chemistry between a modified antibody and functionalized liposomes, representing the innovation of the work. It selectively delivered higher doxorubicin (Dox) to ovarian cancerous SKOV-3 cells overexpressing PD-L1. The nanocarrier, with an optimized size (100–200 nm) and a doxorubicin concentration (1 μg/mL), effectively reduces systemic toxicity and enhances drug accumulation in tumor cells through site-specific delivery. The success of this approach lays the groundwork for the development of next-generation targeted therapies for ovarian and other PD-L1-expressing cancers.